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Abstract
Background: The potential harms of some medications may outweigh their potential benefits (inappropriate
medication use). Despite recommendations to avoid the use of potentially inappropriate medications (PIMs) in
older adults, the prevalence of PIM use is high in different settings including residential aged care. However, it
remains unclear what the costs of these medications are in this setting. The main objective of this study was to
determine the costs of PIMs in older adults living in residential care. A secondary objective was to examine if there
was a difference in costs of PIMs in a home-like model of residential care compared to an Australian standard
model of care.
Methods: Participants included 541 participants from the Investigation Services Provided in the Residential Environment
for Dementia (INSPIRED) Study. The INSPIRED study is a cross-sectional study of 17 residential aged care facilities in
Australia. 12 month medication costs were determined for the participants and PIMs were identified using the 2015
updated Beers Criteria for older adults.
Results: Of all of the medications dispensed in 1 year, 15.9% were PIMs and 81.4% of the participants had been exposed
to a PIM. Log-linear models showed exposure to a PIM was associated with higher total medication costs (Adjusted
β = 0.307, 95% CI 0.235 to 0.379, p < 0.001). The mean proportion (±SD) of medication costs that were spent on PIMs in
1 year was 17.5% (±17.8) (AUD$410.89 ± 479.45 per participant exposed to a PIM). The largest PIM costs arose from
proton-pump inhibitors (34.4%), antipsychotics (21.0%) and benzodiazepines (18.7%). The odds of incurring costs from
PIMs were 52% lower for those residing in a home-like model of care compared to a standard model of care.
Conclusions: The use of PIMs for older adults in residential care facilities is high and these medications represent a
substantial cost which has the potential to be lowered. Further research should investigate whether medication reviews
in this population could lead to potential cost savings and improvement in clinical outcomes. Adopting a home-like
model of residential care may be associated with reduced prevalence and costs of PIMs.
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Background
Polypharmacy, i.e. the use of five or more medications,
is high in residential aged care facilities [1]. Furthermore,
the potential harms of some medications may outweigh
their potential benefits (inappropriate medication use).
Inappropriate polypharmacy is not only associated with
an increased risk of adverse drug reactions, but also an
increased risk of disability, unplanned hospitalizations
and mortality [2].
In 2015 the Beers Criteria for potentially inappropriate
medication (PIM) use in older adults were updated by
the American Geriatrics Society [3]. The Beers Criteria
provide a comprehensive list of PIMs; the majority of
the medications included in the Beers Criteria are
strongly recommended to be avoided in older adults,
and the evidence to support these recommendations was
largely rated as moderate or high quality [3]. PIMs, ac-
cording to the Beers Criteria, have been associated with
increased risks of hospitalization and mortality in older
people in residential care [4]. In addition to their poten-
tial adverse health effects and negative effect on quality
of life, the use of PIMs may also lead to higher health
care costs [5, 6].
An additional Beers Criteria list specific for older
adults with dementia or cognitive impairment is also in-
cluded in the 2015 update. The evidence to support the
development of this list was rated as moderate quality
by the authors of the Beers Criteria. The authors
strongly recommend avoiding medications within this
list in older adults with dementia or cognitive impair-
ment because these medications may cause adverse
central nervous system effects, and because of the asso-
ciation of antipsychotics with a greater risk of stroke and
mortality in people with dementia [3].
Despite recommendations to avoid the use of PIMs in
older adults, the prevalence of PIM use has been shown
to be high in a number of different settings including
residential aged care. Approximately one half of aged
care residents have been previously shown to be exposed
to PIMs [7]. However, it remains unclear what the costs
of these medications are in this setting.
It has not previously been shown if different models of
residential care can affect the use of PIMs. Models of
residential care for older adults that aim to provide small
group home-like environments and encourage independ-
ence for the residents have been of increasing interest
[8, 9]. The World Health Organization stated that these
models ‘hold promise’ for the residents, family members
and staff [9]. However, the effectiveness of these
home-like residential care models needs to be further
examined [10]. Living in home-like residential care
models may improve quality of life for residents [8],
whether this is reflected in exposure to PIMs has not
previously been investigated.
The objectives of this study were to determine expos-
ure to and cost of PIMs according to the 2015 updated
Beers Criteria for all older adults living in residential
care and the additional criteria for people living with
cognitive impairment and dementia. Further, we exam-
ined if there was a difference in the amount spent on
these medications in a home-like residential care model
compared to a standard model of care.
Methods
Study participants
The Investigating Services Provided in the Residential
Environment for Dementia (INSPIRED) study is a cross-
sectional observational study of residential aged care
facilities in Australia and was designed to include
participants with cognitive impairment and dementia.
The study received ethics approval from the Flinders
Social and Behavioural Research Ethics Committee. The
study aimed to include facilities from areas representing
different socioeconomic backgrounds, geographic loca-
tions (e.g. rural vs metropolitan locations) and different
states of Australia. In total, 17 facilities in Australia
(including South Australia, New South Wales, Western
Australia, and Queensland) participated in the study. Par-
ticipants self-consented to be involved in the study or,
where more severe cognitive impairment was present, in-
formed consent and information was provided by a proxy,
usually a close family member (76% of the participants).
To be eligible for participation in the study the partici-
pants needed to: 1) have been a permanent resident in the
facility for 12 months or more, 2) have not been in imme-
diate palliative care, 3) have no complex medical or family
issues which would impede their participation and 4) have
a family member available and willing to participate on
their behalf if a proxy was required.
In total, 1323 potential participants were assessed for
eligibility and 901 were eligible to participate; of these
60% (n = 541) consented. Data collection was completed
between January 2015 and February 2016.
Medication use
Medication use was primarily based on dispensing re-
cords obtained from the appropriate pharmacy. Data for
dispensing of the medication in the 365 days prior to the
study start date for the facility was collected (hereafter
referred to as 12 month medication records). Of the
study participants, 3.5% (n = 19) did not have pharmacy
records available, and reviews of their medication charts
were undertaken instead. For two of the facilities (both
standard model facilities) the pharmacy records only re-
ported a single instance for the initial dispensing date of
the medication, rather than all dates of provision of the
medication, hence, Pharmaceutical Benefits Scheme
(PBS) records were used to determine medication use
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and costs. In Australia, under the PBS, the government
subsidises costs of many prescription medications for
Australian residents. Accordingly, the majority of dis-
pensed medications will be found in PBS records.
Potentially inappropriate medications
PIMs were identified using the 2015 updated Beers
Criteria [3]. Only the medications which are listed as
PIMs for all older adults (i.e. not those which are
dependent on diagnosis) were considered for analysis of
utilisation in all participants. Participants were deemed
to have been exposed to a PIM if they had been pre-
scribed at least one medication included in the Beers
Criteria in the previous 12 months. Furthermore, we also
completed a subgroup analysis to examine the Beers
Criteria specific for people with cognitive impairment and
dementia in addition to the Beers Criteria for all older
adults. Only participants with a Psychogeriatric Assessment
Scale-Cognitive Impairment Scale (PAS-Cog) score of more
than 4 and/or a formal diagnosis of dementia were included
in this secondary analysis. As the Beers Criteria were
developed for the USA, some medications were added to
the PIMs lists by research pharmacists to allow for the
Australian register of pharmaceutical products; these
medications were in the same classes as medications that
were included in the Beers Criteria lists (Additional file 1:
Table S1).
Costs of the medications
The costs of the medications were based on the
Dispensed Price for Maximum Quantity (DPMQ) for the
medications extracted from the PBS [11]. The DPMQ
incorporates the “price ex-manufacturer, including all
fees, mark-ups and patient contributions” [12]. The
medication codes were matched to the DPMQ costs as
of the 1st March 2016 PBS i.e. costs at the time of com-
pletion of the study. Where a DPMQ for a medication
was not available in the 1st March 2016 listings the PBS
cost for the nearest available month was used.
The 12 month cost of each participant’s PIMs was cal-
culated and estimated as a proportion of their total
medication costs for the 12 months. Costs are reported
in Australian dollars (AUD). Where US dollars are re-
ported a March 2016 exchange rate of $1.00 AUD to
$0.7814 US was used [13].
Models of residential care
The INSPIRED study includes some facilities which have
adopted a home-like model of residential care, in
addition to more standard large-scale facilities. These
home-like models of residential care are small houses
specifically designed and built to provide person-centred
care for residents with dementia, in an environment that
looks and feels more like a domestic home. These
facilities aim to encourage residents to live in a more in-
dependent manner and to contribute to the domestic
duties of the units. The facilities which had a home-like
model were defined by each having at least five of the
following six key components: 1) small size (maximum
15 residents), 2) accessible outdoor areas which residents
can use independently, 3) continuity of care staff allo-
cated to units to ensure continuity of care, 4) meals
cooked within the units, 5) meals put on table for self-
service, 6) residents assist with meal preparation [14].
These descriptive criteria were based on similar models
of care described elsewhere [8, 14–16] and were agreed
in consultation with an advisory group including con-
sumer representatives from the Alzheimer’s Australia
Consumer Dementia Research Network (who were
informal caregivers), clinicians, health services researchers,
and representatives of long-term care providers.
Data assessment
Data collected from the participants included PAS-Cog
scores which provide an overall measure of cognitive
functioning, modified Barthel Index scores which meas-
ure activities of daily living, and Neuropsychiatric
Inventory (NPI) scores which measure behaviour. Social
interaction was defined as visits by family, friends or
neighbours at least once a week. Comorbidities were ex-
tracted from the medical records of the participants and
grouped into one of ten disease categories (excluding
dementia) as used by Cohen-Mansfield and colleagues
[17]. Data collected regarding the facility included infor-
mation from a standardised questionnaire based on the
work of a previous study [18] and was completed by a
member of staff from each facility.
Statistical analysis
The costs were positively skewed and were therefore log
transformed to correct this to a normal distribution. For
the total medication costs there were no zero values and
therefore multivariate linear models of the transformed
costs were used to assess the ratio of mean total medica-
tion costs by exposure to a PIM. As the costs of PIMs
included many zero values, two-part models were used
to assess the ratio of mean total costs of PIMs [19, 20].
First, a logistic regression model was used to predict the
probability of any cost of PIMs more than zero in a
home-like model of care compared to a standard model
of residential care. Second, a log-normal model weighted
by the probability of cost more than zero was used to
model nonzero cost of PIMS associated with residing in
a home-like model of care compared to a standard
model of residential care. Models were adjusted for the
following potential confounding factors: age, sex, marital
status, activities of daily living as measured by the
modified Barthel Index, social interactions, number of
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comorbidities, NPI scores and PAS-Cog scores. The
level of statistical significance was set at p < 0.05. All
analyses were completed using Stata v.14.0 (Stata Corp
LP, College Station, TX, USA).
Results
Characteristics of the participants
The mean (±SD) age of the participants was 85.5 (±8.5)
years old and 74.5% (n = 403) were female. Of the total
participants, 82.8% (n = 448) had some level of cognitive
impairment based on their PAS-Cog score and 64.3%
(n = 348) had a dementia diagnosis.
No medication data were available for eight of the par-
ticipants; the final sample comprised of 533 participants
(98.5%). In this study, 81.4% (n = 434) of the participants
had been exposed to a PIM during the 12 month period.
Of all of the medications dispensed in this period, 15.9%
were PIMs. Those who were not exposed to a PIM were
more likely to be older (p = 0.005), have a diagnosis of
dementia (p = 0.002) and live in a home-like model of
residential care (p = 0.02) (Table 1).
Costs of all medications over 12 months
The mean (±SD) number of different types of medica-
tions that participants were exposed to over the
12 month period was 14.5 (±6.5). The mean (±SD) cost
for all medications in the 12 month period was
AUD$1991.86 (±1538.76) (US$1556.44 (±1202.47)).
Costs of potentially inappropriate medications
Table 2 shows the proportions of each type of PIM
using the list of PIMs for all older adults. The most
common PIMs included proton-pump inhibitors
prescribed for > 8 weeks (42.2% exposed to a proton-
pump inhibitor prescribed for > 8 weeks in the previous
12 months), benzodiazepines (37.9%) and antipsychotics
(30.6%). The prevalence of other PIMs were all relatively
low (< 10%). The prevalence of antidepressants classified
as PIMs was 6.4%, however, the prevalence of any
antidepressant was high (52.5%) and these should be
used with caution in older adults according to the
Beers Criteria.
Table 3 shows the costs of the PIMs. The mean (±SD)
cost for all PIMs in the 12 month period was AUD$410.89
(±479.45) (US$ 327.07 (±374.64)) per participant. The
mean (±SD) proportion of total medication costs that
were PIMs was 17.5% (±17.8). When examining the differ-
ent classes of PIMs the largest mean (±SD) costs in the
12 month period were for proton-pump inhibitors
(AUD$139.54 (±163.58) US$109.04 (±127.82)) and anti-
psychotics (AUD$85.11 (±202.83) US$66.50 (±158.49)).
Those who were exposed to a PIM were more likely to
have higher total medication costs (β = 0.307, 95% CI
0.235 to 0.379, p < 0.001), after adjusting for potential con-
founding factors (Table 4).
Potentially inappropriate medications by model of
residential care
Four facilities (23.5%) were classified as a home-like model
of residential care including 22.2% (n = 120) of the partici-
pants. These home-like facilities all provided specialised
dementia care and 98.3% of the participants in these
facilities had a diagnosis of dementia. The first part of
the two-part model (logistic regression model) estimates a
significant odds ratio of e(−0.735) = 0.48 (p = 0.008), indicat-
ing that the odds of incurring any costs from PIMs was
52% lower for those living in a home-like model of resi-
dential care, after adjusting for potential confounding fac-
tors. The second part of the model (log-normal model)
indicates residing in a home-like model of care was mar-
ginally associated (p = 0.064) with lower costs of PIMs
over 12 months (mean cost ratio = e-0.277 = 75.8%, there-
fore 24.2% lower costs) after accounting for those with
zero costs (Table 5).
Table 1 Characteristics of the study participants, by potentially inappropriate medication (PIM) exposure
Characteristic All participants (n = 541) Participants prescribed
at least one PIM (n = 434)
Participants not prescribed
a PIM (n = 99)
P-value
Age, mean (SD) 85.5 (8.5) 84.9 (8.9) 87.9 (6.4) 0.005
Female, n (%) 403 (74.5) 323 (74.4) 77 (77.8) 0.487
Married, n (%) 137 (25.3) 111 (25.7) 24 (24.2) 0.765
Modified Barthel Index, median (IQR) 35.0 (9.0–71.0) 37.0 (10.0–72.0) 25.0 (6.0–62.0) 0.060
Number of comorbidities, mean (SD) 3.7 (1.4) 3.7 (1.4) 3.5 (1.5) 0.348
Neuropsychiatric Inventory, median (IQR) 7.0 (3.0–12.0) 7.0 (3.0–13.0) 6.0 (3.0–11.0) 0.152
Dementia diagnosis, n (%) 348 (64.3) 265 (62.1) 77 (78.6) 0.002
PASCog Score, median (IQR) 15.0 (6.0–21.0) 14.2 (5.0–21.0) 18.0 (9.0–21.0) 0.050
Residing in a home-like model of residential care, n (%) 120 (22.2) 89 (20.5) 31 (31.3) 0.020
Based on the standard list of PIMs from the Beers Criteria for all older adults, not including the additional list of PIMs for older adults with dementia
Abbreviations: IQR Inter-quartile range, PAS-Cog Psychogeriatric Assessment Scale – Cognitive Impairment Scale
P values are from chi-squared or Mann-Whitney tests
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Costs of potentially inappropriate medications for
dementia and cognitive impairment: Subgroup analysis
In total, 86.5% (n = 461) of the participants had dementia or
cognitive impairment and were included in this analysis. Of
these participants, 81.3% (n = 375) had been exposed to a
PIM that is not recommended for older adults and/or con-
traindicated in dementia or cognitive impairment. The
mean (±SD) cost for these PIMs in the 12 month period
was AUD$416.93 (±499.86). The mean (±SD) proportion of
total medication costs that were PIMs for those with cogni-
tive impairment and dementia was 18.3% (±18.3). When
examining the different classes of PIMs the largest mean
(±SD) costs in the 12 month period were for proton-pump
inhibitors prescribed for > 8 weeks (AUD$126.07 ± 156.35)
and antipsychotics (AUD$93.76 ± 211.87). The logistic
regression model estimates a significant odds ratio of
e(−0.724) = 0.48 (p = 0.011), indicating that the odds of
incurring any costs from PIMs was 52% lower for those
living in a home-like model of residential care, after
adjusting for potential confounding factors. The log-normal
model indicates residing in a homelike model of care was
marginally associated (p = 0.051) with the lower costs of
PIMs over 12 months (mean cost ratio = e-0.284 = 75.3%,
indicating 24.7% lower costs) after excluding those with
zero costs.
Discussion
This is the first study that has examined the 12 month
costs of PIMs in older adults in residential care with a
high prevalence of cognitive impairment and dementia
using the updated Beers Criteria, to the author’s know-
ledge. This analysis has demonstrated that over 80% of
participants had been exposed to a PIM over a 12 month
period and approximately 16% of all medications dis-
pensed in this 12 month period were PIMs. Those ex-
posed to a PIM were more likely to have higher total
medication costs. The highest exposures to PIMs were for
proton-pump inhibitors prescribed for more than 8 weeks,
benzodiazepines and antipsychotics. Furthermore, those
who resided in a home-like model of residential care were
less likely to incur any costs due to PIMs.
Few previous studies have provided period prevalence
estimates for PIMs over 12 months in residential aged
care settings. Previous studies have shown the preva-
lence of PIMs taken at a single time point (point
prevalence) by older adults in residential care settings to
be approximately 50% [7, 21]. However, this estimate has
varied in different populations; in a Brazilian study this
was reported to be as high as 82.6%, with 32% of all
medications being PIMs [22]. The fact that the period
prevalence of PIMs in this study over 12 month period
was high is unsurprising. The population examined in
this study had a high prevalence of cognitive impairment
and dementia; all resided in an aged care facility and the
mean age was over 85 years. It is therefore expected that
exposure to PIMs would be higher than in studies of
community-dwelling older adults or relatively younger
age groups. For instance, PIM exposure has been shown
to be higher in women aged 85 years and over [23]. The
current study adds to the body of evidence by using the
2015 updated Beers Criteria and examining a population
of long-term aged care residents with a high prevalence
of cognitive impairment and dementia.
In this study the highest exposure to PIMs were due
to proton-pump inhibitors, benzodiazepines and antipsy-
chotics. This profile of use is similar to previous studies
which have found proton-pump inhibitors to be the
largest cause of PIM exposure for older people [24].
Proton-pump inhibitor use in older adults has been
associated with an increased risk of bone loss and
fractures, Clostridium difficile infection, community-
acquired pneumonia, and vitamin and mineral deficien-
cies [25]. There was also high-exposure to psychotropic
Table 2 Number of participants prescribed potentially
inappropriate medications over a 12 month period
PIM All participantsa
(n = 533), n %
Participants with cognitive
impairment and dementiab
(n = 461), n (%)
Any PIM 434 (81.4) 375 (81.3)
Antidepressants 34 (6.4) 22 (4.8)
Antiemetic n/a 26 (5.6)
Antihistaminesc 3 (0.6) 11 (2.4)
Anti-infective 27 (5.1) 24 (5.2)
Antimuscarinics n/a 13 (2.8)
Antiparkinsonian agents 2 (0.4) 1 (0.2)
Antispasmodics 2 (0.4) 2 (0.4)
Antipsychotics 163 (30.6) 157 (34.1)
Antithrombotics 14 (2.6) 11 (2.4)
Benzodiazepines 202 (37.9) 166 (36.0)
Cardiovasculard 40 (7.5) 35 (7.6)
Central alpha blockers 6 (1.1) 5 (1.1)
Endocrine 52 (9.8) 41 (8.9)
Gastrointestinale 51 (9.6) 42 (9.1)
H2-receptor antagonists n/a 12 (2.6)
Pain medications 29 (5.4) 24 (5.2)
Peripheral alpha-1
blockers
8 (1.5) 6 (1.3)
Proton-pump inhibitors 225 (42.2) 183 (39.7)
aIncludes all study participants with complete medication data and PIMs were
based on the standard list of PIMs from the Beers Criteria for all older adults
bParticipants with cognitive impairment and dementia: sub-group analysis which
only includes participants with a PAS-Cog score > 4 or a formal diagnosis of
dementia and the PIMs were based on the standard list of PIMs from the Beers
Criteria for all older adults and the additional list of PIMs from the Beers Criteria for
people with cognitive impairment and dementia. cFirst generation antihistamines
only considered for PIMs for older adults; ddigoxin, nifedipine and
amiodarone; emetoclopramide
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PIMs (benzodiazepines and antipsychotics), which are
frequently associated with adverse effects in older adults,
including falls, hospitalization, cardiovascular complica-
tions, adverse mental state changes and mortality in
older people in residential care [26]. The use of antipsy-
chotics for some of the participants in the current study
may be appropriate, given the high prevalence of demen-
tia in this study. However, guidelines recommend use of
antipsychotics only in rare cases for those with extreme
behavioural and psychological symptoms of dementia
(BPSD) [27, 28], and therefore the use of antipsychotics
in 30% of the study population at some stage during the
previous 12 months indicates that a significant propor-
tion of use is likely to be inappropriate. Furthermore, al-
though we found the prevalence of antidepressants
classified as PIMs to be quite low, we found the preva-
lence of any antidepressant use was high (over 50%).
Some of the use of these additional antidepressants
(SSRIs and SNRIs) may also be inappropriate in some
cases as these medications are recommended to be used
with caution in older adults and SSRIs should be avoided
in those with a history of falls or fractures according to
the Beers Criteria and also antidepressants may not be
effective for depression associated with dementia [27].
Deprescribing is defined as the process of withdrawal
of an inappropriate medication, supervised by a health-
care professional with the goal of managing polyphar-
macy and improving outcomes [29]. The high exposure
to PIMs in our study indicates that older adults in resi-
dential care could be an appropriate target group for
deprescribing. This may not only benefit the residents,
but may also lead to cost saving. In addition to the direct
costs of PIMs there are additional indirect costs of man-
aging associated adverse drug events. Deprescribing of
PIMs may reduce both direct and indirect costs
Table 3 The estimated costs of medications in a 12 month
period amongst participants prescribed a potentially
inappropriate medication
All participants who were
prescribed at least one PIMa
(n = 434)
Costs (AUD$),
mean (SD)
Proportion of total
PIM costs, mean % (SD)
Total PIMs cost 410.89 (479.45) –
Daily PIMs cost 0.92 (1.26) –
Cost of PIMs by type of medication
Antidepressants 8.21 (32.63) 2.1 (9.2)
Antihistaminesc 0.87 (12.60) 0.4 (5.5)
Anti-infective 8.30 (44.17) 2.1 (10.8)
Antiparkinsonian agents 0.37 (5.99) 0.1 (1.2)
Antispasmodics 0.83 (16.09) 0.2 (2.8)
Antipsychotics 85.11 (202.83) 21.0 (33.6)
Antithrombotics 8.57 (53.79) 1.6 (10.3)
Benzodiazepines 54.78 (93.58) 18.7 (29.1)
Cardiovasculard 5.40 (26.16) 4.8 (19.8)
Central alpha blockers 3.45 (29.98) 0.5 (5.9)
Endocrine 77.23 (382.14) 7.4 (22.5)
Gastrointestinale 6.30 (38.54) 3.0 (13.6)
Pain medications 10.23 (54.50) 3.4 (15.2)
Peripheral alpha-1 blockers 1.71 (13.82) 0.4 (3.8)
Proton-pump inhibitors 139.54 (163.58) 34.4 (38.3)
Participants with cognitive impairment or dementia who were
prescribed at least one PIMb (n = 375)
Total PIMs cost 416.93 (499.86) –
Daily PIMs cost 1.14 (1.37) –
Cost of PIMs by type of medication
Antidepressants 6.66 (31.34) 1.6 (8.3)
Antiemetic 9.24 (58.76) 1.5 (8.6)
Antihistamines 4.83 (38.06) 1.3 (8.9)
Anti-infective 8.72 (46.04) 2.2 (11.2)
Antimuscarinics 3.15 (22.88) 1.0 (7.0)
Antiparkinsonian agents 0.31 (6.09) 0.03 (0.7)
Antispasmodics 0.96 (17.31) 0.2 (3.1)
Antipsychotics 93.76 (211.87) 22.7 (34.1)
Antithrombotics 6.84 (46.89) 1.3 (8.8)
Benzodiazepines 50.59 (89.44) 17.3 (28.0)
Cardiovasculard 5.62 (27.61) 4.9 (20.3)
Central alpha blockers 3.29 (29.33) 0.5 (6.1)
Endocrine 74.39 (394.53) 6.8 (21.8)
Gastrointestinale 6.11 (37.88) 3.0 (13.6)
Table 3 The estimated costs of medications in a 12 month
period amongst participants prescribed a potentially
inappropriate medication (Continued)
All participants who were
prescribed at least one PIMa
(n = 434)
Costs (AUD$),
mean (SD)
Proportion of total
PIM costs, mean % (SD)
H2-receptor antagonists 4.60 (27.99) 1.6 (10.3)
Pain medications 10.39 (56.89) 3.2 (14.6)
Peripheral alpha-1 blockers 1.42 (12.74) 0.3 (3.6)
Proton-pump inhibitors 126.07 (156.35) 30.5 (36.3)
aIncludes all study participants with complete medication data exposed to a PIM
in the 12 month period; PIMs were based on the Beers Criteria for all older adults
bParticipants with cognitive impairment and dementia: sub-group analysis
includes participants with a PAS-Cog score > 4 or a formal diagnosis of dementia
exposed to a PIM in the 12 month period; PIMs were based on the standard list
of PIMs from the Beers Criteria for all older adults and the additional list of PIMs
from the Beers Criteria for people with cognitive impairment and dementia
All costs are based on Dispensed Price for Maximum Quantity (DPMQ) pricing
from the Pharmaceutical Benefits Scheme (PBS). cOnly first generation
antihistamines are considered for PIMs for all older adults; ddigoxin, nifedipine
and amiodarone; emetoclopramide
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associated with their use. However, substitution with
alternatives, such as non-pharmacological interventions,
carries its own costs. Future studies should investigate
the cost-effectiveness of deprescribing PIMs in residen-
tial care. Several randomised controlled trials have found
positive effects of interventions in residential care
facilities (e.g., educational interventions for clinical staff,
medication reviews) in reducing the use of inappropriate
medications; however, the effects on clinical outcomes
remain unclear [30–36].
In Australia, around AUD$9 billion is spent annually
(2011–2012 figure) by the government on residential
aged care services and in the same year there were
187,941 residential aged care places [37]. Furthermore,
medications constitute a high proportion of all direct
health costs in residential aged care [38]. Based on the
numbers of people exposed to a PIM, the average
amount spent on PIMs per participant in this study, and
the feasibility of stopping PIMS in practice [39], redu-
cing exposure to half of these PIMs could result in an
annual direct saving in medication costs of approxi-
mately AUD$38 million in Australia.
Participants who were living in a home-like model of
residential care had a lower risk of incurring any costs due
to PIMs over the one year period compared to those living
in standard models of care. The prevalence and costs of
PIMs in different models of residential care have not been
previously explored. Residential care facilities which offer
a home-like model of care have been shown to favourably
impact quality of life, behavioural symptoms and emo-
tional well-being of the residents [8, 10, 40, 41]. Reasons
for lower exposure to PIMs in these settings cannot be de-
termined in the current study, but a possible improvement
in quality of life seen in the residents may lead to fewer
behavioural symptoms and a lower proportion of PIM use
in these settings. However, there was no difference in NPI
scores between those who had and had not been exposed
to a PIM. Also, staff in alternative models of residential
care may be able to accommodate and manage changed
behaviours more effectively using alternative approaches
than is possible in standard models of care. Further re-
search is needed to clarify the effectiveness of home-like
Table 4 Associations between exposure to potentially
inappropriate medications and total medication costs: log
transformed linear regression models
β (95% CI) P-value
All participants
Exposed to a PIM, Unadjusted model 0.333 (0.261, 0.406) <0.001
Exposed to a PIM, Adjusted modela 0.307 (0.235, 0.379) <0.001
Participants with cognitive impairment or dementia
Exposed to a PIM, Unadjusted model 0.341 (0.264, 0.417) <0.001
Exposed to a PIM, Adjusted modela 0.319 (0.243, 0.395) <0.001
Reference group is participants not exposed to a PIM
aLog transformed linear regression models adjusted for age, sex, marital status,
activities of daily living as measured by the modified Barthel Index, social
interactions, number of comorbidities, Neuropsychiatric Inventory (NPI) scores
and PAS-Cog scores
PIMs were based on the standard list of PIMs from the Beers Criteria for all
older adults
Participants with cognitive impairment and dementia: sub-group analysis
includes participants with a PAS-Cog score > 4 or a formal diagnosis of dementia
exposed to a PIM in the 12 month period; PIMs were based on the standard list
of PIMs from the Beers Criteria for all older adults and the additional list of PIMs
from the Beers Criteria for people with cognitive impairment and dementia
All costs are based on Dispensed Price for Maximum Quantity (DPMQ) pricing
from the Pharmaceutical Benefits Scheme (PBS)
Table 5 Associations between models of residential care and costs of potentially inappropriate medications: two-part models
Unadjusted Adjusteda
β (95% CI) P-value β (95% CI) P-value
All participants
First part: logistic regression model
Residing in a home-like model of care −0.569 (−1.054, −0.085) 0.021 −0.735 (−1.283, −0.188) 0.008
Second part: log-normal linear model
Residing in a home-like model of care −0.191 (−0.461, 0.078) 0.165 −0.277 (−0.570, 0.016) 0.064
Participants with cognitive impairment or dementia
First part: logistic regression model
Residing in a home-like model of care −0.654 (−1.15, 0.160) 0.010 −0.724 (−1.280, −0.169) 0.011
Second part: log-normal linear model
Residing in a home-like model of care −0.194 (−0.457, 0.068) 0.147 −0.284 (−0.567, 0.002) 0.051
Reference group is participants residing in a standard Australian model of care
aTwo-part-models adjusted for age, sex, marital status, activities of daily living as measured by the modified Barthel Index, social interactions, number of
comorbidities, Neuropsychiatric Inventory (NPI) scores and PAS-Cog scores
PIMs were based on the standard list of PIMs from the Beers Criteria for all older adults
Participants with cognitive impairment and dementia: sub-group analysis which only includes participants with a PAS-Cog score > 4 or a formal diagnosis of
dementia exposed to a PIM in the 12 month period; PIMs were based on the standard list of PIMs from the Beers Criteria for all older adults and the additional list
of PIMs from the Beers Criteria for people with cognitive impairment and dementia
All costs are based on Dispensed Price for Maximum Quantity (DPMQ) pricing from the Pharmaceutical Benefits Scheme (PBS)
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care models on different outcomes for residents and staff
[10]. Those that had not been exposed to a PIM were
more likely to have a diagnosis of dementia and this may
be due to a higher proportion of people living with
dementia residing in a home-like model of care, but the
definitive reason for this association could not be deter-
mined in this study.
Strengths and limitations
This study collected comprehensive data on an older
population living in residential care, including a high
prevalence of people with cognitive impairment and de-
mentia. The dispensing data were collected from elec-
tronic records held by the individual pharmacies used by
the facilities and they are inclusive of all of the medica-
tions dispensed to the individuals over the study period.
We were unable to include PIMs based on diagno-
sis (apart from cognitive impairment and dementia);
therefore only medications which are PIMs for all
older adults were included so this may be an under-
estimate of the actual costs of PIMs in this popula-
tion. There is also a difference in formularies between
Australia and the US where the Beers Criteria were
developed as some medications are not available in
Australia and some medications were added to adapt the
Beers Criteria to an Australian setting (4% of PIMs were
additional medications added). Polypharmacy has been
identified as a risk factor for exposure to PIMs [7].
However, we could not directly examine the preva-
lence of polypharmacy in this study as we examined
12 month period prevalence of medications rather
than point prevalence.
Facilities which have adopted a home-like model of
care as described in this study were all located in one
state in Australia and these facilities are specifically
designed for people with dementia. However, we have
adjusted for many potential confounding factors includ-
ing PAS-Cog scores and NPI scores between the models
of care.
Conclusions
Exposure to PIMs is very common amongst older adults
with a high prevalence of cognitive impairment and de-
mentia permanently residing in aged care facilities. The
financial cost of PIMs is high and has the potential to be
lowered by reducing the prevalence of PIMs in this
setting. Facilities which had adopted a home-like model
of residential care were less likely to incur costs due to
PIMs. Further research should investigate whether
deprescribing of PIMs in older people in residential
facilities could lead to cost savings and improvements in
outcomes such as mortality, hospitalization and quality
of life.
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